

C5 vs Pathway Expression

Legend: -0.584(0.030) 6.55e-05 1.40e-03

IC(Δ) P-val FDR

| Pathway | IC(Δ) | P-val | FDR |
|---|---------------|----------|----------|
| ABDULRAHMAN_KIDNEY_CANCER_VHL_DN | -0.572(0.039) | 6.55e-05 | 1.40e-03 |
| KRIEG_HYPOXIA_NOT_VIA_KDM3A | -0.567(0.036) | 6.55e-05 | 1.40e-03 |
| GROSS_HYPOXIA_VIA_HIF1A_ONLY | -0.557(0.061) | 6.55e-05 | 1.40e-03 |
| TRACEY_RESISTANCE_TO_IFNA2 | -0.548(0.005) | 6.55e-05 | 1.40e-03 |
| SU_KIDNEY | -0.543(0.049) | 6.55e-05 | 1.40e-03 |
| TRACEY_RESISTANCE_TO_IFNA2_UP | -0.531(0.032) | 6.55e-05 | 1.40e-03 |
| REACTOME_P130CAS_LINKAGE_TO_MAPK_SIGNALING_FOR_INTEGRINS | -0.529(0.017) | 6.55e-05 | 1.40e-03 |
| BIOCARTA_INTRINSIC_PATHWAY | -0.521(0.025) | 6.55e-05 | 1.40e-03 |
| REACTOME_GRB2_SOS_PROVIDES_LINKAGE_TO_MAPK_SIGNALING_FOR_INTERGRINS | -0.519(0.056) | 6.55e-05 | 1.40e-03 |
| LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_UP | -0.516(0.028) | 6.55e-05 | 1.40e-03 |
| SMID_BREAST_CANCER_NORMAL_LIKE_DN | -0.513(0.030) | 6.55e-05 | 1.40e-03 |
| CROMER_METASTASIS | -0.512(0.055) | 6.55e-05 | 1.40e-03 |
| GROGER_EMT_DN | -0.505(0.045) | 6.55e-05 | 1.40e-03 |
| WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_UP | -0.505(0.026) | 6.55e-05 | 1.40e-03 |
| P53_DN.V1_DN | -0.500(0.016) | 6.55e-05 | 1.40e-03 |
| AIGNER_ZEB1_TARGETS | -0.498(0.025) | 6.55e-05 | 1.40e-03 |
| JIANG_HYPOXIA_CANCER | -0.497(0.041) | 6.55e-05 | 1.40e-03 |
| REACTOME_INTEGRIN_ALPHAIIIB_BETA3_SIGNALING | -0.483(0.027) | 6.55e-05 | 1.40e-03 |
| BIOCARTA_AMI_PATHWAY | -0.480(0.033) | 6.55e-05 | 1.40e-03 |
| KANG_IMMORTALIZED_BY_TERT | 0.552(0.028) | 6.55e-05 | 1.76e-04 |
| MILICIC_FAMILIAL_ADENOMATOUS_POLYPOSIS | 0.553(0.025) | 6.55e-05 | 1.76e-04 |
| OXFORD_RALA_AND_RALB_TARGETS | 0.554(0.025) | 6.55e-05 | 1.76e-04 |
| INAMURA_LUNG_CANCER_SCC | 0.554(0.021) | 6.55e-05 | 1.76e-04 |
| KRAS.300_UP.V1 | 0.554(0.680) | 6.55e-05 | 1.76e-04 |
| REACTOME_APOPTOTIC_CLEAVAGE_OF_CELL_ADHESION_PROTEINS | 0.556(0.036) | 6.55e-05 | 1.76e-04 |
| BOSCO_EPITHELIAL_DIFFERENTIATION_MODULE | 0.565(0.025) | 6.55e-05 | 1.76e-04 |
| ESC_J1_UP_EARLY.V1 | 0.566(0.666) | 6.55e-05 | 1.76e-04 |
| CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL | 0.566(0.021) | 6.55e-05 | 1.76e-04 |
| P53_DN.V1 | 0.567(0.019) | 6.55e-05 | 1.76e-04 |
| LANDIS_BREAST_CANCER_PROGRESSION_UP | 0.568(0.010) | 6.55e-05 | 1.76e-04 |
| LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_DN | 0.571(0.020) | 6.55e-05 | 1.76e-04 |
| SMID_BREAST_CANCER_NORMAL_LIKE | 0.571(0.022) | 6.55e-05 | 1.76e-04 |
| CROMER_METASTASIS_DN | 0.572(0.014) | 6.55e-05 | 1.76e-04 |
| WAMUNYOKOLI_OVARIAN_CANCER_LMP_UP | 0.573(0.047) | 6.55e-05 | 1.76e-04 |
| CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP | 0.577(0.061) | 6.55e-05 | 1.76e-04 |
| JAEGER_METASTASIS_DN | 0.579(0.046) | 6.55e-05 | 1.76e-04 |
| TAUBE_EMT_DN | 0.583(0.014) | 6.55e-05 | 1.76e-04 |
| OSADA_ASCL1_TARGETS | 0.590(0.037) | 6.55e-05 | 1.76e-04 |
| COLDREN_GEFITINIB_RESISTANCE_DN | 0.648(0.043) | 6.55e-05 | 1.76e-04 |
| CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP | | | |